TW200501956A - Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine - Google Patents
Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraineInfo
- Publication number
- TW200501956A TW200501956A TW093108719A TW93108719A TW200501956A TW 200501956 A TW200501956 A TW 200501956A TW 093108719 A TW093108719 A TW 093108719A TW 93108719 A TW93108719 A TW 93108719A TW 200501956 A TW200501956 A TW 200501956A
- Authority
- TW
- Taiwan
- Prior art keywords
- migraine
- oxoquinazolin
- tyrosyl
- sumatriptan
- lysyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a process for the treatment or prevention of headache, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of the hydrochloride of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-y1)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) and of a therapeutically effective amount of the anti-migraine substance sumatriptan or a physiologically acceptable salt thereof, and the corresponding pharmaceutical compositions and the preparation thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10314617A DE10314617A1 (en) | 2003-04-01 | 2003-04-01 | Use of the hydrochloride of the active ingredient base 1- [N2- [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] - D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine in combination with sumatriptan for the treatment of migraines |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200501956A true TW200501956A (en) | 2005-01-16 |
Family
ID=32980861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093108719A TW200501956A (en) | 2003-04-01 | 2004-03-30 | Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1631282A1 (en) |
JP (1) | JP2006522044A (en) |
AR (1) | AR043793A1 (en) |
CA (1) | CA2520930A1 (en) |
CL (1) | CL2004000686A1 (en) |
DE (1) | DE10314617A1 (en) |
TW (1) | TW200501956A (en) |
UY (1) | UY28251A1 (en) |
WO (1) | WO2004087134A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102322A1 (en) * | 2004-04-20 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines |
US20110212980A1 (en) * | 2008-10-22 | 2011-09-01 | Novartis Ag | Combinations for the treatment of migraine |
EP3416618A1 (en) | 2016-02-19 | 2018-12-26 | ZP Opco, Inc. | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines |
US11660264B2 (en) | 2017-08-23 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
US11660265B2 (en) | 2018-06-28 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10139410A1 (en) * | 2001-08-17 | 2003-02-27 | Boehringer Ingelheim Pharma | Use of BIBN4096 in combination with other anti-migraine drugs for the treatment of migraines |
DE10206770A1 (en) * | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim Pharma | New, stable acid addition salts of the quinazolinone derivative CGRP antagonist BIBN4096, useful for the treatment of migraine, in the form of an inhalable powder |
-
2003
- 2003-04-01 DE DE10314617A patent/DE10314617A1/en not_active Withdrawn
-
2004
- 2004-03-26 CA CA002520930A patent/CA2520930A1/en not_active Abandoned
- 2004-03-26 JP JP2006504871A patent/JP2006522044A/en active Pending
- 2004-03-26 EP EP04723571A patent/EP1631282A1/en not_active Withdrawn
- 2004-03-26 WO PCT/EP2004/003210 patent/WO2004087134A1/en not_active Application Discontinuation
- 2004-03-30 TW TW093108719A patent/TW200501956A/en unknown
- 2004-03-30 CL CL200400686A patent/CL2004000686A1/en unknown
- 2004-03-31 UY UY28251A patent/UY28251A1/en not_active Application Discontinuation
- 2004-03-31 AR ARP040101065A patent/AR043793A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006522044A (en) | 2006-09-28 |
AR043793A1 (en) | 2005-08-10 |
DE10314617A1 (en) | 2004-10-14 |
EP1631282A1 (en) | 2006-03-08 |
CL2004000686A1 (en) | 2005-02-04 |
WO2004087134A1 (en) | 2004-10-14 |
UY28251A1 (en) | 2004-11-08 |
CA2520930A1 (en) | 2004-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
WO2002048183A3 (en) | Compositions of peptide crystals | |
JO3404B1 (en) | Liquid pharmaceutical composition containing an erythropoietin derivative | |
TW200633694A (en) | Composition and method for treating asthma | |
UA90518C2 (en) | Pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, comprising a narcotic active ingredient and amine | |
IL145430A0 (en) | N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same | |
NZ516782A (en) | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | |
CA2433585A1 (en) | Pharmaceutical compositions containing donepezil hydrochloride | |
MXPA04001364A (en) | Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine. | |
TW200602035A (en) | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | |
WO2005014572A8 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
TW200638927A (en) | Bambuterol and integrin inhibitor combination | |
SE0102440D0 (en) | New compound | |
MX2023012521A (en) | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino )-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroet hyl)pyrrolidine-1-carboxamide and salts thereof. | |
HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
TW200501956A (en) | Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine | |
MXPA06003122A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist. | |
TW200700075A (en) | Roflumilast and integrin inhibitor combination and method of treatment | |
SE0002729D0 (en) | Novel compound form | |
MXPA05011064A (en) | Combinations of paroxetine and 4- (s) - (4-acetyl -piperazin-1-yl) -2- (r)- (4-fluoro-2 -methyl-phenyl -piperidine -1-carboxylic acid [1- (r) -(3, 5-bis-trifluoromethyl -phenyl) -ethyl] methylamide for treatment of depression and / or anxiety. | |
WO2002055022A3 (en) | Active metabolite of antifungal compound | |
SG155885A1 (en) | Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile | |
ECSP045241A (en) | Powder inhalation product containing the CGRP antagonist, BIBN4096, and procedure for its preparation | |
MY131159A (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
TW200516077A (en) | Powder formulation containing the CGRP antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder |